Post COVID-19 CYTOKINE Testing (Long Covid)

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: CYTOKINE, IL-6 HS, Interleukin6 Highly Sensitive ELISA

Interleukin 6, Highly

Interleukin-6 (IL-6), Serum - To evaluate the level of IL-6 in serum samples.
*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through Quest Diagnostics. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 Quest Diagnostics laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

The Post COVID-19 CYTOKINE Testing (Long Covid) test contains 1 test with 1 biomarker.

Post COVID-19 CYTOKINE Testing (Long Covid)

Test contains:

  • Interleukin-6, Highly Sensitive, ELISA (also known as CYTOKINE)

Cambridge researchers say that markers in our blood- 'fingerprints' of infection- could help identify individuals who have been infected by SARS-CoV-2, the coronavirus that causes COVID-19.

A patient who has never had a confirmed diagnosis of COVID-19 may have asymptomatic or mild disease and be missed by antibody tests.

The team has found a molecule known as a cytokine that is produced by T cells in response to infection and persists in the blood for a long time after infection.

Researchers have found a cytokine that is produced in response to infection by T cells and can be detected for several months - and potentially years - following infection.

The team's pilot study also found a particular biomarker in patients with long COVID. Their work suggests these patients produce a second type of cytokine, which persists in patients with long COVID compared to those that recover quickly. This cytokine might be one of the drivers behind the many symptoms that patients experience. Therefore, it could prove useful for diagnosing long COVID. Further research is needed to confirm these findings. However, this is a promising development that could improve our understanding of and ability to diagnose long COVID.

 

 

 

Customer Reviews